All In Biotech

Drug Trial Radar · NCT06137157

Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome

A Randomized, Double-Blind, Vehicle-Controlled, First-in-Human Safety, Tolerability and Proof-of-Concept Study of Topical ATR12-351 in Adults With Netherton Syndrome

Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6

Actual

Start

Jun 16, 2024

Primary completion

Jul 7, 2026

Study completion Jul 7, 2026

Sponsor

Lead sponsor
Azitra Inc.Industry
Sponsor type
Industry
First posted
Nov 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this clinical trial are to evaluate the safety and tolerability of topically applied ATR12-351, to understand what the body does to ATR12-351, and to observe treatment benefits of the drug in approximately 12 adult patients with Netherton Syndrome (NS). ATR12-351 will be applied to skin lesions on one side of the body, while the vehicle control will be applied to similar lesion on the other side of the body twice daily for 2 weeks.

Conditions

  • Netherton Syndrome

Interventions

  • ATR12-351Drug

    Topical ointment containing ATR12-351, a LEKTI-secreting strain of S. epidermidis

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: 84 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford University

    Palo Alto, California

  • Yale University

    New Haven, Connecticut

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.